New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|November 2, 2011
Supplements and Featured Publications
- Improving Outcomes in Chronic Kidney Disease: Optimizing Management of Cardiovascular Diseases [CME/
- Volume 17
- Issue 15 Suppl
Improving Outcomes in Chronic Kidney Disease: Optimizing Management of Cardiovascular Diseases
Advertisement
Instructions
After reading “Improving Outcomes in Chronic Kidney Disease: Optimizing Management of Cardiovascular Diseases,” complete the program evaluation and select the 1 best answer to each of the posttest questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5